Stock SUVEN SUVEN LIFE SCIENCES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Suven Life Sciences Limited NSE India S.E.

Equities

SUVEN

INE495B01038

Biotechnology & Medical Research

Market Closed - NSE India S.E.
Other stock markets
 07:42:32 2024-04-30 am EDT 		5-day change 1st Jan Change
110.4 INR -0.81% Intraday chart for Suven Life Sciences Limited +6.15% +36.78%
Apr. 15 Suven Life Sciences to Present Phase-2 Positive Results on Samelisant (SUVN-G3031) at American Academy of Neurology 2024 Annual Meeting, Denver, USA CI
Feb. 06 Suven Life Sciences Announces Randomization of First Patient in Phase-2 POC Clinical Trial of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder Study in USA CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 21,358 33,208 2,724 8,961 13,484 10,570
Enterprise Value (EV) 1 18,643 31,158 2,637 8,545 13,012 8,302
P/E ratio 17.3 x 38.2 x -2.89 x -12.4 x -9.69 x -7.31 x
Yield 0.89% 0.57% - - 1.08% -
Capitalization / Revenue 3.41 x 5 x 18.5 x 63.7 x 113 x 77.8 x
EV / Revenue 2.98 x 4.69 x 17.9 x 60.7 x 109 x 61.1 x
EV / EBITDA 9.24 x 19 x -2.28 x -10.7 x -10.6 x -6.58 x
EV / FCF 67.1 x -38.6 x -3.26 x -12.2 x -21.1 x -10 x
FCF Yield 1.49% -2.59% -30.7% -8.22% -4.74% -9.95%
Price to Book 2.78 x 4 x 1.9 x 8.3 x 14 x 2.82 x
Nbr of stocks (in thousands) 127,282 127,282 127,282 127,282 145,382 218,074
Reference price 2 167.8 260.9 21.40 70.40 92.75 48.47
Announcement Date 7/20/18 7/20/19 8/24/20 7/12/21 7/11/22 7/11/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 6,255 6,638 147.1 140.7 119.5 135.9
EBITDA 1 2,017 1,639 -1,154 -797.8 -1,227 -1,261
EBIT 1 1,772 1,386 -1,194 -832.8 -1,262 -1,319
Operating Margin 28.32% 20.88% -811.96% -591.8% -1,056.14% -970.34%
Earnings before Tax (EBT) 1 1,955 1,587 -1,064 -774.7 -1,220 -1,183
Net income 1 1,237 869.4 -942.2 -721.5 -1,220 -1,183
Net margin 19.77% 13.1% -640.71% -512.69% -1,020.82% -869.95%
EPS 2 9.718 6.831 -7.402 -5.670 -9.570 -6.633
Free Cash Flow 1 277.7 -806.3 -808.3 -702.4 -616.1 -826.3
FCF margin 4.44% -12.15% -549.68% -499.11% -515.56% -607.82%
FCF Conversion (EBITDA) 13.77% - - - - -
FCF Conversion (Net income) 22.45% - - - - -
Dividend per Share 2 1.500 1.500 - - 1.000 -
Announcement Date 7/20/18 7/20/19 8/24/20 7/12/21 7/11/22 7/11/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 2,715 2,050 87.1 416 472 2,268
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 278 -806 -808 -702 -616 -826
ROE (net income / shareholders' equity) 17.2% 10.9% -49.3% -57.4% -120% -50.2%
ROA (Net income/ Total Assets) 12.8% 8.85% -30.8% -33.5% -66.7% -33.2%
Assets 1 9,658 9,828 3,063 2,151 1,828 3,564
Book Value Per Share 2 60.30 65.30 11.30 8.490 6.610 17.20
Cash Flow per Share 2 1.600 0.8700 1.150 0.7300 0.3600 1.700
Capex 1 400 973 23.9 63 198 28.9
Capex / Sales 6.4% 14.66% 16.22% 44.8% 165.44% 21.29%
Announcement Date 7/20/18 7/20/19 8/24/20 7/12/21 7/11/22 7/11/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.40% 42.19B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 40.15B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+5.27% 24.63B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.67% 18.2B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.02% 12.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.28% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+14.62% 10.4B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-4.86% 9.94B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. SUVEN Stock
  4. SUVEN Stock
  5. Financials Suven Life Sciences Limited